SeraCare announces $20 million contract.LOS ANGELES--(BUSINESS WIRE)--Feb. 21, 1997--SeraCare Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). :SERC) Friday announced a three-year contract valued at more than $20 million to provide source plasma to NABI Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :NABI) of Boca Raton, Fla., one of the leading companies in the blood- products industry. Barry D. Plost, chairman, president and chief executive officer of SeraCare, commented: ``Becoming a plasma supplier to NABI will diversify our customer base considerably, and the increased revenues will facilitate our ongoing planned growth. We are looking forward to a long relationship with NABI.'' NABI, a fully integrated biopharmaceutical company, has a broad product portfolio and significant R&D capabilities focused on the development and commercialization of products that prevent and treat autoimmune and infectious diseases. NABI currently has 11 products in its clinical pipeline for indications including HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. , hepatitis viruses, staph infections and cytomegalovirus. NABI also has two immunotherapeutic products already on the market: H-BIG, for the prevention of hepatitis B, and WhinRho SD, for the treatment of Immune Thrombocytopenic Purpura immune thrombocytopenic purpura n. See idiopathic thrombocytopenic purpura. immune thrombocytopenic purpura Idiopathic thrombocytopenic purpura, see there (ITP ITP - Intent to Package , an immune- platelet disorder) and for the suppression of Rh isoimmunization. SeraCare, one of the top 10 companies in the plasma-collection industry, owns and operates source plasma-collection centers throughout the United States and sells its products to major pharmaceutical-manufacturing companies for use in the making of plasma-derived therapeutic and diagnostic products. SeraCare is also licensed by the Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) to collect and sell Cytomegalovirus Antibody Plasma and Tetanus Antibody Plasma. CONTACT: SeraCare Inc., Los Angeles Barry D. Plost, 310/772-7777 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion